Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Blood

Volumn 116, Issue 11, 2010, Pages 1990-1991

  Sanchorawala, Vaishali ^a   Finn, Kathleen T ^a   Fennessey, Salli ^a   Shelton, Anthony ^a   Doros, Gheorghe ^a   Zeldis, Jerome B ^b   Seldin, David C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; BONE MARROW BIOPSY; CLINICAL TRIAL; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77956922981     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295485     Document Type: Letter

References (5)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596.
2. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009;7(9):947-960.
3. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496. (Pubitemid 46105943)
4. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470. (Pubitemid 46105939)
5. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)